EGFR mutations (5–10%) [21], amplification (20–30%), and overexpression (30–80%) in human esophageal SCC and AC have provided the rationale for targeting EGFR in esophageal cancer [22]. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.